Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public markets pitfalls.

Today, we focus on Mydecine Innovations Group (MYCO.NEO), a Canadian-based psychedelics company developing psychedelics drug candidates for the treatment of PTSD as well as smoking cessation.

Enjoy!